---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-26-000611"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:57:44.403901+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M

## Summary
- Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.
- Adjusted EBITDA loss $2.4M improved from $5.1M loss; EPS $(0.02) vs $(0.21).
- Specialty Pharmacy revenue up 78% YoY; record Part D fills.
- Medicare Advantage lives to reach 200,000 in Florida effective July 1, 2026.
- CMS Enhancing Oncology Model saved ~$2M in period 3; full-year guidance reaffirmed.

## SEC filing metadata
- accession: 0001079973-26-000611
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000611/0001079973-26-000611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000611/toi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-26-000611
- JSON: https://secwatch.observer/filing/0001079973-26-000611.json
- Plain text: https://secwatch.observer/filing/0001079973-26-000611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.